The surgeon wants it. Value analysis has not heard of you.
We put your ads in front of every name on the committee, clinical, supply chain, finance, and the physician champion, so the approval process does not start from zero.
The problem
Deals die in value analysis, and the loss looks like nothing.
You have a rep network and clinical evidence, and your motion depends on a surgeon or department lead falling in love with the device.
Then it hits value analysis. A committee that has never met you, has no clinical stake, and evaluates on cost, contract compliance and risk. Your champion has to carry you through a process they do not control, armed with a brochure.
Deals die there constantly, and the loss looks like nothing. No rejection, just a meeting that keeps getting rescheduled.
Who has to say yes
The buying committee on this deal
Physician or surgeon champion
Wants it, has no budget authority.
Value Analysis Committee
The actual gate: clinical, nursing, supply chain, finance.
Supply chain or materials management
Cares about GPO contracts and standardization.
CFO or VP Finance
Cares about total cost and reimbursement.
Biomed or clinical engineering
On anything with a service or integration component.
Nursing leadership
Whose workflow changes.
Your rep sees the surgeon. Nobody sees the other five. That is the gap.
What sets it off
The moments that create the deal
What we do differently here
Built for how this market actually buys
We cannot and will not replace your rep network. What we do is warm the committee around the champion, so when it reaches value analysis, four of the six people have seen your clinical data, your outcomes, and your cost story for months.
On channel and compliance: medical device targeting runs primarily on LinkedIn and programmatic. Platform policy restricts audiences that could suggest health-related information, so Meta plays a limited role here and we are explicit about that upfront. Every claim in every ad goes through your regulatory review before it runs, no exceptions, and we build that into the timeline.
Proof
Real operators. Real outcomes.
AfterSchool HQ
The closest analog in our portfolio. A purchase that required superintendents, technology directors, curriculum heads and finance leads to all agree, a committee structure very close to value analysis. Meetings booked in week one. Seven-figure deal closed within the engagement window.
We will be straight with you on the meeting about what we have and have not proven in medical devices specifically.
Fit
You are a fit if
The rest of the machine
The same system runs behind every vertical we serve
The six-step system
Named list, message sprint, omni-channel warming, qualification, SDR follow-up, reporting.
Take a look →The two-path system
One fast lane for buyers ready now, one warm lane for the rest. Nobody falls through.
Take a look →The guarantee
What we commit to, in writing, before you spend a dollar on media.
Take a look →Your four options
In-house, agency, coach, or us. The full comparison table sits on the homepage.
Take a look →Next step
Get your free Pipeline Diagnostic.
We will map the named buyers in your market, show you what the first 90 days looks like, and tell you plainly if this is not a fit.